What is Allena Pharmaceuticals Financial Strength?
Allena Pharmaceuticals has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Allena Pharmaceuticals did not have earnings to cover the interest expense.
As of today, Allena Pharmaceuticals's Altman Z-Score is 0.00.
Competitive Comparison of Allena Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Allena Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allena Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Allena Pharmaceuticals's Financial Strength falls into.
Allena Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Allena Pharmaceuticals's Interest Expense for the
months ended in Jun. 2022 was $-0.12 Mil. Its Operating Income for the
months ended in Jun. 2022 was $-6.92 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.00 Mil.
Allena Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2022 is
| Allena Pharmaceuticals did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Allena Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Jun. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Allena Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
One Newton Executive Park, Suite 202, Newton, MA, USA, 02462
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Executives
| Louis Md Brenner |
officer: See Remarks |
RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140 |
| Mark J. Fitzpatrick |
director |
101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
| Richard D Katz |
officer: Chief Financial Officer |
4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703 |
| Edward Wholihan |
officer: Chief Financial Officer |
C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
| Ann Calby Miller |
director |
C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462 |
| Allene M. Diaz |
director |
C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462 |
| Hack Andrew A. F. |
director |
300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142 |
| Bessemer Venture Partners Vii L.p. |
10 percent owner |
C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538 |
| Hbm Biocapital Ii Lp |
10 percent owner |
11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH |
| James N Topper |
director, 10 percent owner |
550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301 |
| Fhm Vi, L.l.c. |
10 percent owner |
601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
| Robert I Tepper |
director, 10 percent owner |
201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215 |
| Third Rock Ventures Ii, L.p. |
10 percent owner |
29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
| Robert Alexander |
director |
508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
| Alexey L Margolin |
director, officer: Chief Executive Officer |
C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139 |
Allena Pharmaceuticals (Allena Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALNAQ has been successfully added to your